Owlet Announces FDA-Clearance Of BabySat Prescription Pulse Oximetry Sock For Infants
Portfolio Pulse from Benzinga Newsdesk
Owlet has announced FDA clearance for its BabySat prescription pulse oximetry sock for infants, which will help monitor oxygen levels and heart rate in newborns.
June 20, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Owlet's FDA clearance for BabySat prescription pulse oximetry sock for infants may lead to increased demand and revenue.
Owlet's BabySat sock has received FDA clearance, which is a significant milestone for the company. This approval will allow the product to be marketed and sold in the US, potentially leading to increased demand and revenue for Owlet. The news is highly relevant and important for investors, as it directly impacts the company's growth prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100